What is Mounjaro?

Mounjaro is a weekly tirzepatide injection for type 2 diabetes in adults and children age 10 and older.

Source for this answer

Source: Current FDA label, checked 2026-08-12

Explore Mounjaro

Dosage scheduleSee every labeled step from 2.5 mg to 15 mg.Side effectsSee common trial results, serious warnings and later FDA reports.Cost and coverageCompare the list price, published cash offers and key limits.Storage and travelCheck the label rules for temperature, travel and time out of the fridge.About TirzepatideSee the medicine behind Mounjaro and any other brands that use it.

Approved uses

What is Mounjaro approved to treat?

Adults with type 2 diabetes, together with diet and exercise, to improve blood sugar.

Labeled maintenance: No named set — the label steps up in 2.5 mg increments while blood sugar needs more help, to a ceiling of 15 mg

Children age 10 and older with type 2 diabetes, together with diet and exercise.

Labeled maintenance: The same step pattern, stopping at 10 mg rather than 15 mg

Adults with type 2 diabetes and established heart or blood vessel disease. This use lowers the risk of heart attack, stroke and heart-related death.

Labeled maintenance: The label specifies a 2.5 mg weekly start, with further increases only if more blood sugar control is needed

Not an approved use: The Mounjaro label covers neither weight loss nor sleep apnea. Its trials measured weight change, but that is not what the label approves it for.

The product itself

Available forms and strengths

Single-dose pen

2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL

1 dose

Single-dose vial

2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL

1 dose

Multi-dose vial

10 to 60 mg per 2.4 mL, giving 2.5 to 15 mg per 0.6 mL dose

4 doses

Single-patient-use KwikPen

10 to 60 mg per 2.4 mL, giving 2.5 to 15 mg per dose

4 doses

Key product facts

What matters first

Medicine: Tirzepatide
How often: Once weekly, at any time of day
Starting dose: 2.5 mg
Highest labeled dose: 15 mg

Eli Lilly and Company makes Mounjaro under NDA 215866. Mounjaro comes as a shot under the skin.

Same medicine, different label

How is Mounjaro different from Zepbound?

Mounjaro and Zepbound both contain tirzepatide. Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight-related care. Their dose plans are not the same.

Read the Zepbound overview

5primary sources, each with the day we read it — open the documents used on this page

Mounjaro (tirzepatide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-09-13FDA label
Drugs@FDA approval history — NDA 215866, Mounjaro (tirzepatide) injectionretrieved 2026-08-12FDA label
FDA approval letter, NDA 215866 — Mounjaro (tirzepatide) injection, glycemic control in adults with type 2 diabetesretrieved 2026-08-12FDA label
FDA supplement approval letter, NDA 215866/S-039 — expansion of the Mounjaro type 2 diabetes indication to pediatric patients aged 10 years and older (trial I8F-MC-GPGV)retrieved 2026-08-12FDA label
FDA supplement approval letter, NDA 215866/S-044 and S-045 — Mounjaro heart-risk reduction and 2.5 mg for ongoing blood sugar controlretrieved 2026-09-13FDA label

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer